Chardan Capital Reiterates Their Buy Rating on Nightstar Therapeutics Limited (NITE)


Chardan Capital analyst Gbola Amusa reiterated a Buy rating on Nightstar Therapeutics Limited (NITE) today and set a price target of $40. The company’s shares opened today at $12.01, close to its 52-week low of $9.59.

Amusa wrote:

“We understand this trial is sufficiently powered to demonstrate statistical significance, if positive results are achieved. This change comes a few months after the publication of draft guidance from the FDA on retinal GT which indicates a strong preference for inclusion of natural history data as part of overall asset development (see our 12 July 2018 research). We note the company sees this newly-designated phase II/III study as the 1st of 2 controlled trials required for registration of this asset.”

According to TipRanks.com, Amusa is a 5-star analyst with an average return of 17.8% and a 46.0% success rate. Amusa covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Logicbio Therapeutics Inc, and Catalyst Biosciences Inc.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Nightstar Therapeutics Limited with a $35.14 average price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $29.55 and a one-year low of $9.59. Currently, Nightstar Therapeutics Limited has an average volume of 154K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Nightstar Therapeutics PLC is a clinical-stage gene therapy company, which engages in the development and commercialization of novel one-time treatments for patients suffering from rare inherited retinal diseases. Its pipeline includes NSR-REP1, for the treatment of choroideremia; NSR-RPGR, for the treatment of X-linked retinitis pigmentosa; and NSR-BEST1, for the treatment of vitelliform macular dystrophy. The company was founded by Robert MacLaren on July 6, 2017 and is headquartered in London, the United Kingdom.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts